Journals / Nöropsikiyatri Arşivi / 2009 / Cilt: 46 - Sayı: 2

After star-D: Treatment resistant depression

Star-D sonrası: Sağaltıma direnen depresyon (SDD)

Pages
61–69
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Since the available data show that all the medication alternatives have a very limited success after two failures with different antidepressants, considering ECT in that step can be rational.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although the lack of evidence in literature for the treatment of resistant depression has not been totally overcome by Star-D Study, and the basic questions are still unanswered; we can assume that now we have much more reliable data regarding the topic.
📊
Key Findings & Data:The recent data can be seen as such: 1.The definition of treatment-resistant depression as ‘not to have response (or remission) after two appropriate trials of different antidepressants’ seems to be true. 2.
💡
Conclusion & Impact:Since the available data show that all the medication alternatives have a very limited success after two failures with different antidepressants, considering ECT in that step can be rational.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İlaç kombinasyonları · Depresyon · Antidepresif ajanlar

Abstract

Although the lack of evidence in literature for the treatment of resistant depression has not been totally overcome by Star-D Study, and the basic questions are still unanswered; we can assume that now we have much more reliable data regarding the topic. The recent data can be seen as such: 1.The definition of treatment-resistant depression as ‘not to have response (or remission) after two appropriate trials of different antidepressants’ seems to be true. 2. Antidepressant therapy should start as monotherapy with optimal dose. Most of the patients require 6-8 weeks for response or remission. A dose increase towards the maximal or the highest tolerated dose must start in the 4th week, if there is no response. The same dose can be maintained if there is a partial response. 3. In case of an absolute unresponsiveness in the 6 th week, switching the antidepressant can be considered after the exclusion of the factors of pseudo-resistance; and a partial response may suggest an augmentation or combination strategy. 4. The predictors of those strategies are unknown yet. For a severe depression it may be safer to choose augmentation or combination instead of switch. For a worsening depression, on the other hand, ECT may be the safest and most correct option. 5. At present, the data show that augmentation and combination have almost the same efficacy in case of resistance. 6. Regarding the available data, T3, lithium or buspirone options can be considered for augmentation. 7. SSRI+bupropione, venlafaxine+mirtazapine, SSRI+TCA, TCA+mianserine, SSRI+mirtazapine, and SSRI+reboxetine can be seen as options for combination strategy. 8. In regard to switching, venlafaxine, TCA’s, bupropione, mirtazapine, and another SSRI seem to be the options in case of an SSRI‘s failure. 9. Since the available data show that all the medication alternatives have a very limited success after two failures with different antidepressants, considering ECT in that step can be rational.

Özet

Dirençli depresyon sağaltımı konusunda literatürdeki kanıt yokluğu Star-D çalışmasıyla da hala tam aşılamamış ve temel sorular hala yanıtsız olsa da, şimdi elimizde çok daha güvenilir veriler bulunmaktadır. Bu veriler şöyle özetlenebilir: 1. Dirençli depresyon tanımı için, iki uygun antidepresan denemesiyle yeterli düzelme olmaması ölçütü doğru görünmektedir. 2. Antidepresan sağaltım optimal doz monoterapi şeklinde başlamalıdır. Yanıt ve tam düzelme, çoğu hastada 6-8 haftaya gereksinir. Sağaltımın dördüncü haftasında yanıt yoksa, maksimal ya da tolere edilen en yüksek doza doğru bir doz artımı başlatılmalıdır. Kısmi yanıt halinde ayni dozda kalınabilir. 3. Altıncı haftadaki tam yanıtsızlıkta, yalancı direnç etkenleri dışlandıktan sonra, antidepresan değiştirilebilir; kısmi yanıtta ise güçlendirme ya da birleştirme seçilebilir. 4. Bu stratejilerin öngörücüleri henüz belirsizdir. Ağır bir depresyonda, değiştirme yerine, güçlendirme veya birleştirme daha güvenli olabilir. Giderek ağırlaşmakta olan bir depresyonda ise, EKT en güvenli seçenek olabilir. 5. Güçlendirme ve birleştirme stratejileri, şimdilik benzer etkinlikte görünmektedir. 6. Güçlendirme için T3, lityum ve buspiron akla gelebilir. 7. Birleştirme için, SSRI+bupropion, venlafaksin+mirtazapin, SSRI+TSA, TSA+Mianserin, SSRI+Mirtazapin ve SSRI+Reboksetin anımsanabilir. 8. Bir SSRI’a başarısızlıkta değiştirme açısından, venlafaksin, TSA’lar, bupropion, mirtazapin ve başka bir SSRI olası seçeneklerdir. 9. Eldeki veriler, iki denemeye yanıtsızlıkta diğer ilaç denemelerinin de çok sınırlı bir başarısını bildirdiğinden, bu durumda daha fazla vakit kaybetmeden EKT’ye geçilmesi gerektiğini ileri süren görüşler haklı olabilir.

🔖

Cite This Article

YAZICI, Ö. (2009). After star-D: Treatment resistant depression. Nöropsikiyatri Arşivi, Cilt: 46 - Sayı: 2, 61–69. https://ajindex.com/articles/292689

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: Definition and treatment approaches. J Clin Psychiatry 1990; 51(Suppl.6):39-47
  2. Fawcett J. Progress in treatment-resistant and treatment-refractory depression: We still have a long way to go. Psychiatric Annals 1994; 24:214-21
  3. Hornig-Rohan M, Amsterdam JD. Clinical and biological correlates of treatment-resistant depression: An overview. Psychiatric Annals 1994; 24:220-7
  4. Thase ME, Rush AJ. Treatment-resistant depression. FE Bloom, DJ Kupfer, editörler. Psychopharmacology: The Fourth Generation of Progress içinde. New York: Raven Press 1995; s. 1081-97
  5. Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58(Suppl.13):23-9
  6. Rush AJ, Fava M, Wisniewski SR et al. Sequenced treatment alternatives to relieve depression (Star-D): rational and design. Control Clin Trials 2004; 25:119-42
  7. Triverdi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR-D: Implications for clinical practice. Am J Psychiatry 2006; 163:28-40
  8. Rush AJ, Trivedi MH, Wisniewski SR ve ark. Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression. N Engl J Med 2006; 354:1231-42
  9. Trivedi MH, Fava M, Wisniewski SR et al. Medication Augmentation after the Failure of SSRIs for Depression. N Engl J Med 2006; 354:1243-52
  10. Fava M, Rush J, Wisniewski SR et al. A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. Am J Psychiatry 2006; 163:1161-72
  11. Nierenberg AA, Fava M, Trivedi MH et al. A Comparison of Lithium and T3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. Am J Psychiatry 2006; 163:1519-30
  12. McGrath PJ, Stewart JW, Fava M et al. Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. Am J Psychiatry 2006; 163:1531-41
  13. Nelson JC. The Star-D study: A four-course meal that leaves us wanting more. Am J Psychiatry 2006; 163:1864-6
  14. Sussman N, Joffe RT. Augmentation of antidepressant medication. J Clin Psychiatry 1998; 59 (Suppl.5):3-5
  15. Adli M, Baethge C, Heinz A et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? Eur Arch Psychiatry Clin Neurosci